| Without STI (n= 275) | With STI (n = 20) | P value |
---|
Negative (n) | Positive (n) | Negative (n) | Positive (n) |
---|
H3 binding IgG | 267 | 8 | 19 | 1 | 0.4732 |
A35 binding IgG | 266 | 9 | 19 | 1 | 0.5100 |
A29 binding IgG | 250 | 25 | 17 | 3 | 0.2921 |
B6 binding IgG | 267 | 48 | 17 | 3 | 0.6377 |
E8 binding IgG | 110 | 165 | 8 | 12 | 0.5879 |
M1 binding IgG | 263 | 12 | 20 | 0 | 0.4235 |
Vaccinia binding IgG | 274 | 1 | 19 | 1 | 0.1312 |
Neutralizing antibody | 246 | 29 | 18 | 2 | 0.6480 |
- With STI, participants with diagnosed Syphilis, Gonorrhea, Chlamydia, genital herpes or genital warts during the 6 months before the enrollment. Without STI, participants without diagnosed STI during the 6 months prior to the enrollment. Participants who were not sure whether they had STIs or not during the 6 months prior to the enrollment were excluded from this analysis. PRNT50 ≥ 30 is classified as a positive neutralizing antibody response